TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Benign Prostatic Hyperplasia, based on medical history~* Voiding symptoms~* Uroflow (max) 5-15mL/sec~Exclusion Criteria:~* Urgent need for prostate surgery~* History of allergic reaction to peptide~* Major organ dysfunction~* Prior surgical treatment of the prostate or bladder~* Current or recent treatment with sexual hormone drugs or 5 α reductase inhibitors or botulinum toxin type a (Botox) within the last 6 months prior to trial medication at Week 0 or with α blockers or saw palmetto within the last 6 weeks prior to trial medication at Week 0~* Urologic disorders including neurogenic bladder dysfunction due to diabetes mellitus or documented neurologic disorder, urethral stricture disease or history of pelvic radiation therapy~* History of acute obstructive, infectious, or neurological disorders of the genitourinary tract within the last 3 months

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetrorelix 78 mg (Type: EXPERIMENTAL): Drug: Cetrorelix 52 mg week 0, and 26 mg week 2, intra muscular-2 doses in 2 weeks and follow up to week 26.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* History of eye allergies within the past 24 months~* Willing to not wear contact lenses at least 72 hours prior to the study start and during the study period~Exclusion Criteria:~* Current eye infection~* Eye surgery within 3 months or vision correction surgery within 6 months~* Any planned surgery during the study or 30 days after the study

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LASTACAFT® (alcaftadine 0.25%) (Type: ACTIVE_COMPARATOR): One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
- Pataday™ (olopatadine 0.2%) (Type: ACTIVE_COMPARATOR): One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
- Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) (Type: PLACEBO_COMPARATOR): One drop of placebo instilled in each eye at Day 0 and Day 14.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Adipokines in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Overweight (Body Mass Index ≥ 25 kilograms per meter squared (kg/m2))~* Adult (18 years or older)~* Chronic hemodialysis patient~* Diabetic (type 2) or insulin resistant~Exclusion Criteria:~* \<18 years old~* No insulin resistance~* Active liver disease~* Class III or IV New York Heart Association heart failure~* Macular edema or hard exudates near macula on fundoscopy~* Current active malignancy (excluding squamous and basal cell skin cancers)~* Active AIDS~* Chronic lung disease requiring supplemental oxygen therapy~* Enrolled in interventional trials using drugs or devices~* Bone break of long bones, vertebrae, or hips in the past three years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pioglitazone (Type: ACTIVE_COMPARATOR): 15 mg/day pioglitazone for 2 weeks, then 30 mg/day for remaining 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 1 placebo pill a day matching the pioglitazone treatment for 26 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven renal cell carcinoma~* CT-confirmed measurable disease~* Disease progression after bevacizumab +/- IFN~* Favorable/intermediate prognosis according to MSKCC~* Nephrectomy~* No contradictions to everolimus~* Age 18 or older~* Written informed consent~Exclusion criteria~* prior TKI's or mTOR inhibitor~* pregnant or nursing~* history of serious cardiac arrhythmia, congestive heart failure, angina pectoris, or other severe cardiovascular disease (i.e., New York Heart Association class III or IV)~* CNS metastases by neurologic exam and/or MRI~* local and/or systemic infections requiring antibiotics within 28 days prior to study entry~* other malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Everolimus (Type: EXPERIMENTAL): All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SPK Study in Afghanistan

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males: age over 4 months;~* Females: age 4 months - 11 years inclusive, or 18 years or older;~* Infection with P. falciparum detected by microscopy at a level of 500-150,000/µL asexual forms;~* Presence of axillary or tympanic temperature ≥ 37.5 °C or oral or rectal temperature of ≥ 38 °C or history of fever during the past 24 h;~* ability to swallow oral medication;~* ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and~* Informed consent from the patient or from a parent or guardian in the case of children under 16 years of age.~Exclusion Criteria:~* Presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO (Appendix 1);~* Infection with another Plasmodium species detected by microscopy not mixed with falciparum;~* Females 18 years or older: a positive pregnancy test or absence of a negative pregnancy test when a pregnancy test is not possible for cultural reasons;~* Breastfeeding~* Presence of severe malnutrition (defined as a child whose growth standard is below -3 z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference \< 110 mm);~* Presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);~* Regular medication, which may interfere with antimalarial pharmacokinetics;~* History of hypersensitivity reactions or contraindications to any of the study medications;

- Gender: ALL
- Minimum Age: 4 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Artesunate + Sulphadoxine-pyrimethamine (Type: EXPERIMENTAL): AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Moderately to severely active ulcerative colitis defined as a 3-component Mayo Clinic score~* Evidence of colonic ulcerative colitis activity on endoscopy~Exclusion Criteria:~* Within 30 days prior to randomization, receipt of any of the following for the treatment of underlying disease: Non-biologic therapies (eg, cyclosporine, tacrolimus, tofacitinib, thalidomide), a non-biologic investigational therapy or an approved non-biologic therapy in an investigational protocol~* Within 60 days prior to randomization, receipt of any of the following: Infliximab, adalimumab, golimumab, certolizumab, vedolizumab, any other investigational or approved biologic agent~* Any prior exposure to natalizumab, efalizumab, or rituximab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Etrasimod Low Dose (Type: EXPERIMENTAL): Oral, low dose, daily for 12 Weeks
- Etrasimod High Dose (Type: EXPERIMENTAL): Oral, high dose, daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Oral, placebo, daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who have confirmed antibody-mediated Pure red cell aplasia (PRCA) are potentially eligible for enrollment into this study.~* Participants must be ≥ 18 years old at the time of consent.~* Erythropoiesis stimulating agents (ESAs) must be discontinued for a minimum of 1 month prior to screening.~* Participant requires periodic transfusions to maintain hemoglobin.~* Hemoglobin \< 10 g/dL for at least 2 measurements or participant has received a transfusion within the past 4 weeks to achieve a hemoglobin \> 10 g/dL.~* Confirmation that an anti-erythropoietin antibody sample was obtained for analysis by the central reference laboratory within 1 month prior to baseline.~* Participants can either be participants with chronic kidney disease not yet requiring renal replacement therapy (participants not on dialysis), those on regular hemodialysis or peritoneal dialysis, or following a renal transplant.~* Participants may or may not have previously been treated with immunosuppressive therapy.~* Pre-menopausal females (with the exception of those who are surgically sterile) must have a negative pregnancy test at screening.~* Written informed consent must be obtained.~Exclusion Criteria:~* Participants already successfully on another erythropoietic agent.~* Abnormal bone marrow findings consistent with the diagnosis of myelodysplasia, a myeloproliferative disorder, hematologic malignancy or evidence of metastatic infiltration.~* Poorly controlled hypertension.~* Previous exposure to any investigational agent within 4 weeks prior to administration of study drug or planned receipt during the study period.~* High likelihood of early withdrawal or interruption of the study.~* Participants who refuse to give informed consent.~* Women who are pregnant, lactating or not using a medically approved birth control.~* Life expectancy \<12 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peginesatide (Type: EXPERIMENTAL): Peginesatide 0.05 mg/kg injection, subcutaneously as a starting dose followed by peginesatide 0.1 mg/kg injection, subcutaneously once every 4 weeks for up to 6 months.~Individual dose of peginesatide injection was modified based on hemoglobin levels. Dose adjustments were made in order to achieve and maintain hemoglobin in the target range of 10.0-12.0 g/dL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of restless legs syndrome with a total score of 15 or more points on the International RLS rating scale (IRLS).~* RLS symptoms interfering with sleep on 3 or more nights per week for at least 6 months.~* PSG confirmation of WASO of at least 60 min, PLMI of 10 or more, and total sleep time of at least 3 hrs and less than 6.5 hrs.~Exclusion Criteria:~* Secondary RLS.~* Daytime RLS symptoms requiring treatment.~* Primary sleep disorder.~* Sleep apnea.~* Night or shift work.~* Concurrent medical disorder that could interfere with efficacy assessment or present a safety concern.~* Pregnant or lactating women.~* Women of child-bearing potential not using acceptable method of birth control.~* Use of prohibited medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- pregabalin (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None
- pramipexole (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Umbilical Cord Serum Eye Drops

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with recurrent corneal erosions~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- umbilical cord serum eyedrops (Type: EXPERIMENTAL): patients with recurrent corneal erosions were treated with 20% umbilical cord serum eye drops 3 to 4 times a day in addition to artificial tears

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Evaluation of the Empower Neuromodulation System in AUD Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Is male or female ≥ 21 year of age at Visit 1~* Has a current diagnosis of alcohol use disorder per DSM-5 by clinician assessment~* Endorses Criterion 4 in DSM-5~* Has a desire to maintain abstinence or, if not abstinent, a desire to reduce or quit alcohol use~* Has a breath alcohol concentration of 0.00% at enrollment~* Is able to provide informed consent~* Is able to understand spoken and written English~* Is capable and willing to follow all study-related procedures~Exclusion Criteria:~* Has been diagnosed with unstable psychosis, epilepsy, peripheral neuropathy, or nerve damage~* Requires acute medical detoxification from alcohol based on a score of 12 or more on the Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-AD)~* Has implanted electrical and/or neurostimulator device (e.g. pacemaker, defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, sacral stimulator, bone growth stimulator, or cochlear implant)~* Has an electrically conductive metal object (e.g. jewelry) that cannot be removed from the palm and will directly contact the gel electrodes of the Empower Neuromodulation System~* Will not, for the duration of the participation in the study, have a living situation that provides regular access to an electrical outlet.~* Is pregnant, breastfeeding, or unwilling to practice birth control during participation in the study~* Has used an investigational drug/device therapy within the past 4 weeks~* Is deemed unsuitable for enrollment in the study by the PI

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Baseline (Type: NO_INTERVENTION): For the first week of the study, participants will not administer treatment with the Empower device. Participants will complete surveys to establish baseline values for each participant.
- Active treatment (Type: EXPERIMENTAL): Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Horizant (Gabapentin Enacarbil) on Augmentation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients with diagnosis of RLS for more than one year.~2. Patients who are on DA therapy for 6 months or longer.~3. Patients who developed Augmentation (on stable dose of DA) lasting for 3 months or longer.~4. Augmentation severity rating scale of 5 to 15.~5. Both males and females~6. Age range = 18-85 year~Exclusion Criteria:~* Known Hypersensitivity to Horizant or Gabapentin products~* Peripheral neuropathy~* Radiculopathy~* Peripheral vascular disease~* Uremia \[abnormal blood urea nitrogen (BUN) or Creatinine on Comprehensive Metabolic Panel (CMP)\]~* Anemia~* Patients who are currently pregnant~* Patients who currently take opioids, lithium, anti-nausea medications (e.g. metoclopramide), dopaminergic antagonists (e.g. Haloperidol), 1st generation antihistamines (e.g. diphenhydramine, pseudoephedrine), anti-psychotic medications and iron therapy.~* Subjects with impaired decision making capability.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- open-label (Type: OTHER): open-label single arm study~Horizant, 600 mg oral once daily at 5 pm for 360 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-anesthesiologist-administered Propofol During the Flexible Bronchoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory patients aged \> 18 years with an indication for flexible bronchoscopy.~Exclusion Criteria:~* tracheostomy~* known allergy to drugs used during procedural sedation~* inability to answer the satisfaction questionnaires~* psychiatric illness, pregnancy~* ASA class IV or V

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Midazolam (Type: ACTIVE_COMPARATOR): In the group of midazolam, the initial dose was 0.05 mg/kg. Additional doses of 2 mg of midazolam were allowed to reach a score level of 3 to 4 in the Observer´s assessment of alertness/ sedation scale. All patients received nalbuphine in a starting dose of 2 mg with additional doses of 1 mg if it was necessary. Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.~Intervention: Transcutaneous CO2 monitor
- Propofol (Type: EXPERIMENTAL): In the group of propofol, the starting dose was 0.1 mg /kg. Additional doses of 10 mg of propofol were allowed to reach a score level of 3 to 4 in the Observer´s assessment of alertness/ sedation scale. All patients received nalbuphine in a starting dose of 2 mg with additional doses of 1 mg if it was necessary. Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.~Intervention: Transcutaneous CO2 monitor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete